

Supplementary material

Mechanism investigation of rifampicin-induced liver injury using comparative toxicoproteomics in mice

Ju-Hyun Kim, Woongshik Nam, SunJoo Kim, Oh Kwang Kwon, Eun Ji Sung, Jung Jae Jo, Riya Shresha, Tae Hee Lee, Tae Won Jeon, Sung Hwan Ki, Hye Suk Lee, and Sangkyu Lee

Supplemental Methods

*Determine of **plasma biochemical** parameters in mouse plasma*

The following parameters were analyzed using an automatic analyzer (7020, Hitachi, Japan): alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, triglyceride, total cholesterol, lactate dehydrogenase (LDH), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), creatine phosphokinase (CPK), glucose, blood urea nitrogen (BUN) and albumin. **The activity of alkaline phosphatase (ALP) was determined according to an instruction manual prepared by the manufacturer (Asan Pharm. Co., Hwasung, Korea).**

CYP activity screening

A CYP probe assay was performed to measure liver microsomal activity in RIF-treated mice. The liver homogenate S9 fraction, 0.1 M potassium phosphate buffer (pH 7.4), CYP probe substrates, and beta-NADPH-generation system (NGS) were mixed and incubated for 1 hour in a total volume of 100 μ L. NGS was composed of 0.1 M glucose-6-phosphate, 10 mg/mL β -NADPH, and 1.0 U/mL glucose-6-phosphate dehydrogenase. The S9 fraction was prepared by centrifugation of the mouse homogenate at 9,000 \times g for 20 minutes. CYP probe substrates were composed of 20 μ M omeprazole for CYP2C and 2.5 μ M midazolam for CYP3A. After incubation, **100 μ L of 0.1% formic acid in acetonitrile** was added to terminate the reaction. After mixing, centrifugation was performed at 13,000 \times g for 10 minutes, and a 10- μ L aliquot was added to the vial for the LC-MS/MS analysis.

Table S1. Plasma biochemical parameters after 14 consecutive days of rifampicin administration in male mice

Dose (mg/kg)	LDH (IU/L)	HDL-C (mg/dL)	LDL-C (mg/dL)	CPK (IU/L)	Glucose (mg/dL)	BUN (mg/dL)	Albumin (mg/dL)
0	823.8 ± 67.8	13.1 ± 0.6	10.5 ± 0.7	468.1 ± 44.7	92.4 ± 3.9	23.1 ± 0.3	3.1 ± 0.1
177	1,626.6 ± 312.6*	20.4 ± 2.8	46.7 ± 5.9	880.1 ± 83.2*	107.6 ± 9.6	23.2 ± 0.2	2.9 ± 0.1
442.5	2,557.4 ± 464.1*	19.4 ± 1.0	54.7 ± 7.2	1,165.9 ± 206.5*	122.3 ± 5.3	23.7 ± 0.2	2.7 ± 0.3

Male ICR mice were orally treated with 177 and 442.5 mg/kg rifampicin in 5% (v/v) DMSO and 25% (v/v) polyethylene glycol (PEG) in water for 14 consecutive days. All animals were subjected to necropsy 24 h after treatment. Value represent means ± SE of 4–6 animals. The asterisks indicate significant differences in comparisons with the vehicle control at P<0.05. LDH; activity of lactate dehydrogenase, HDL-C; content of high-density lipoprotein cholesterol, LDL-C; content of low-density lipoprotein cholesterol, CPK; activity of creatine phosphokinase and BUN; content of blood urea nitrogen. The asterisks indicate the significant differences in comparisons with the vehicle control at P<0.05 (*).

1 **Table S2.** Summary of differentially expressed proteins

Dose	Up-regulated (>1.5)	Down-regulated (<0.667)
177 mg/kg vs. VH	29	27
442.5 mg/kg vs. VH	40	118

2


3

4

5

6

7




8


9 **Figure S1.** Enzyme activity levels of CYP2C-mediated omeprazole 5-hydroxylase (A) and
10 CYP3A-catalyzed midazolam hydroxylase (B). The asterisks indicate the significant
11 differences in comparisons with the vehicle control at $P < 0.05$ (*).

12

Biological process




Cellular component



14
 15 **Figure S2.** Gene ontology functional classification of the quantified proteins based on
 16 biological process (A), and subcellular location (B). The heatmap was generated using the
 17 two-tailed Fisher's exact test was employed to test the enrichment of each differentially
 18 expressed protein with P-value of <0.05 against all identified proteins.

19



20

21 **Figure S3.** Enrichment analysis of KEGG pathway of up-regulated proteins after the oral
 22 administration of 177 mg/kg (A), and 442.5 mg/kg (B) rifampicin.

23